Expression and clinical significance of matrix metalloproteinase-9 in lymphatic invasiveness and metastasis of breast cancer

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Wu, Qiu Wan ^a   Yang, Qing Mo ^a   Huang, Yu Fan ^a   She, Hong Qiang ^a   Liang, Jing ^a   Yang, Qiao Lu ^a   Zhang, Zhi Ming ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GELATINASE B; MESSENGER RNA; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD VESSEL PARAMETERS; BREAST METASTASIS; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; LYMPHATIC MICROVESSEL DENSITY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; BREAST TUMOR; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR INVASION;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84901318945     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097804     Document Type: Article

References (20)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90.
2. Ran S, Volk L, Hall K, Flister MJ (2010)Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 17(4):229-251.
3. El-Gohary YM, Metwally G, Saad RS, Robinson MJ, Mesko T, et al. (2008) Prognostic significance of intratumoral and peritumoral lymphatic density and blood vessel density in invasive breast carcinomas. Am J Clin Pathol 129(4):578-586. (Pubitemid 352029277)
4. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161-174. (Pubitemid 37328786)
5. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, et al. (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10(22):7621-7628. (Pubitemid 39557525)
6. Daniele A, Zito AF, Giannelli G, Divella R, Asselti M, et al. (2010) Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res 30(9):3521-3527.
7. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, et al. (2009) Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 9: 20.
8. Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopatholog 41(3A):154-161.
9. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3(6):1101-8. (Pubitemid 351818697)
10. Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, et al. (2006)First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer 95(12):1611-1625. (Pubitemid 44950785)
11. Suzuki H, Onimaru M, Yonemitsu Y, Maehara Y, Nakamura S, et al. (2010) Podoplanin in cancer cells is experimentally able to attenuate prolymphangiogenic and lymphogenous metastatic potentials of lung squamoid cancer cells. Mol Cancer 9: 287.
12. Mylona E, Nomikos A, Magkou C, Kamberou M, Papassideri I, et al. (2007) The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopatholog 50(3):338-347. (Pubitemid 46169418)
13. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, et al. (2005) Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166(3):913-921. (Pubitemid 40315647)
14. Fohn LE, Rodriguez A, Kelley MC, Ye F, Shyr Y, et al. (2011) D2-40 lymphatic marker for detecting lymphatic invasion in thin to intermediate thickness melanomas: association with sentinel lymph node status and prognostic value-a retrospective case study. J Am Acad Dermatol 64(2):336-345.
15. Niakosari F, Kahn HJ, Marks A, From L (2005)Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endothelium. Arch Dermatol 141(4):440-444. (Pubitemid 40547402)
16. Hasebe T, Yamauchi C, Iwasaki M, Ishii G, Wada N, et al. (2008) Grading system for lymph vessel tumor emboli for prediction of the outcome of invasive ductal carcinoma of the breast. Hum Pathol 39(3):427-436. (Pubitemid 351193070)
17. Rabban JT, Chen YY (2008) D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma. Hum Pathol 39(2):175-183.
18. Bjorklund M, Koivunen E (2005) Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755(1):37-69. (Pubitemid 40720240)
19. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, et al. (2008) Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 122(9):2050-2056. (Pubitemid 351441195)
20. Achen MG, Stacker SA (2008) Molecular control of lymphatic metastasis. Ann N Y Acad Sci 1131: 225-234. (Pubitemid 351758517)